Cytodyn Inc (CYDY)

[ScienceOC]

Another study on Remdesivir...

This paper is from NEJM (DOI: 10.1056/NEJMoa2007016)
Compassionate Use of Remdesivir for Patients with Severe Covid-19

This was not a randomized controlled trial (RCT), which means there was no comparison to placebo.

This paper showed that "clinical improvement was observed in 36 of 53 patients (68%)" But this was NOT RCT. It did not compare to placebo or any other medications.

However Remdesivir showed high adverse effects:

1) A total of 32 patients (60%) reported adverse events during follow-up (Table 2). The most common adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension.

2) A total of 12 patients (23%) had serious adverse events. The most common serious adverse events — multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension — were reported in patients who were receiving invasive ventilation at baseline.

Due to high adverse effects, not sure if Remdesivir is the drug of choice for COVID-19

https://www.nejm.org/doi/full/10.1056/NEJMoa2007016?query=featured_home